Here's Why Novartis (NVS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript
Here's Why Novartis (NVS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Novartis Stock Topped the Market Today
It earned FDA approval for a spinal muscular atrophy drug. This is a version of its existing commercialized SMA treatment, Zolgensma.
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
Novartis plans to cut up to 550 jobs at Swiss facility
Novartis said on Tuesday up to 550 full-time jobs could be cut by the end of 2027 at the Swiss pharmaceutical company's Stein facility near Basel in northern Switzerland.
Novartis AG (NVS) Shareholder/Analyst Call Transcript
Novartis AG ( NVS ) Shareholder/Analyst Call November 20, 2025 4:15 AM EST Company Participants Victor Bulto - President of US Angelika Jahreis - Global Head of Development Unit Immunology, Hepatology & Dermatology Richard Siegel Ingrid Zhang Patrick Horber - President of International Dianne Auclair Rocha Ruchira Glaser Shaun Coughlin Shreeram Aradhye - President of Development & Chief Medical Officer Shiva Malek Dushen Chetty Reshema Kemps-Polanco Fiona Marshall - President of BioMedical Research Norman Putzki - Global Program Head of Neuroscience Tracey Dawson Robert Baloh Aharon Gal - Chief Strategy & Growth Officer Harry Kirsch - Chief Financial Officer Vasant Narasimhan - Chief Executive Officer Steffen Lang - President of Operations Conference Call Participants Michael Leuchten - Jefferies LLC, Research Division Thibault Boutherin - Morgan Stanley, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
Novartis AG (NVS) Shareholder/Analyst Call Transcript
Novartis AG ( NVS ) Shareholder/Analyst Call November 20, 2025 3:00 AM EST Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Conference Call Participants Sachin Jain - BofA Securities, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Matthew Weston - UBS Investment Bank, Research Division Steve Scala - TD Cowen, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Michael Leuchten - Jefferies LLC, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Here's Why Novartis (NVS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
New, effective anti-malaria drug could help fight rising resistance, says Novartis
A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug resistance, the company said on Wednesday as it presented final-stage trial results.
